Medprin Regenerative Medical Stock Current Valuation
| 301033 Stock | 48.32 0.52 1.09% |
Valuation analysis of Medprin Regenerative helps investors to measure Medprin Regenerative's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Medprin Regenerative's Free Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Other Non Cash Items is expected to grow to about 4.1 M, whereas Cash is forecasted to decline to about 26.9 M. Fundamental drivers impacting Medprin Regenerative's valuation include:
Price Book 4.846 | Enterprise Value 3 B | Enterprise Value Ebitda 36.9744 | Price Sales 11.6444 | Trailing PE 46.4615 |
Overvalued
Today
Please note that Medprin Regenerative's price fluctuation is very steady at this time. Calculation of the real value of Medprin Regenerative is based on 3 months time horizon. Increasing Medprin Regenerative's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Medprin Regenerative is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medprin Stock. However, Medprin Regenerative's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 48.32 | Real 38.89 | Hype 48.37 |
The real value of Medprin Stock, also known as its intrinsic value, is the underlying worth of Medprin Regenerative Company, which is reflected in its stock price. It is based on Medprin Regenerative's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Medprin Regenerative's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Medprin Regenerative Medical helps investors to forecast how Medprin stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medprin Regenerative more accurately as focusing exclusively on Medprin Regenerative's fundamentals will not take into account other important factors: Medprin Regenerative Medical Company Current Valuation Analysis
Medprin Regenerative's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Medprin Regenerative Current Valuation | 3.04 B |
Most of Medprin Regenerative's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medprin Regenerative Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Medprin Regenerative Medical has a Current Valuation of 3.04 B. This is 78.87% lower than that of the Health Care Equipment & Supplies sector and 75.57% lower than that of the Health Care industry. The current valuation for all China stocks is 81.74% higher than that of the company.
Medprin Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medprin Regenerative's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medprin Regenerative could also be used in its relative valuation, which is a method of valuing Medprin Regenerative by comparing valuation metrics of similar companies.Medprin Regenerative is currently under evaluation in current valuation category among its peers.
Medprin Fundamentals
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0633 | ||||
| Profit Margin | 0.25 % | ||||
| Operating Margin | 0.39 % | ||||
| Current Valuation | 3.04 B | ||||
| Shares Outstanding | 66.52 M | ||||
| Shares Owned By Insiders | 52.68 % | ||||
| Shares Owned By Institutions | 15.83 % | ||||
| Price To Book | 4.85 X | ||||
| Price To Sales | 11.64 X | ||||
| Revenue | 230.87 M | ||||
| Gross Profit | 220.53 M | ||||
| EBITDA | 107.26 M | ||||
| Net Income | 40.88 M | ||||
| Total Debt | 151.11 M | ||||
| Book Value Per Share | 10.09 X | ||||
| Cash Flow From Operations | 107.69 M | ||||
| Earnings Per Share | 1.04 X | ||||
| Number Of Employees | 278 | ||||
| Beta | -0.09 | ||||
| Market Capitalization | 3.21 B | ||||
| Total Asset | 786.97 M | ||||
| Retained Earnings | 114.02 M | ||||
| Working Capital | 201.59 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 786.97 M | ||||
| Last Dividend Paid | 0.4 |
About Medprin Regenerative Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medprin Regenerative Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medprin Regenerative using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medprin Regenerative Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Medprin Stock
Medprin Regenerative financial ratios help investors to determine whether Medprin Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medprin with respect to the benefits of owning Medprin Regenerative security.